Joseph Edelman - Net Worth and Insider Trading
Joseph Edelman Net Worth
The estimated net worth of Joseph Edelman is at least $6 Million dollars as of 2023-09-24. Joseph Edelman is the Director, 10% Owner of Athira Pharma Inc and owns about 3,114,805 shares of Athira Pharma Inc (ATHA) stock worth over $6 Million. Details can be seen in Joseph Edelman's Latest Holdings Summary section.
Transaction Summary of Joseph Edelman
Joseph Edelman Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Joseph Edelman owns 48 companies in total, including ARYA Sciences Acquisition Corp II (ARYBU) , Athira Pharma Inc (ATHA) , and Quotient Ltd (QTNTQ) among others .
Click here to see the complete history of Joseph Edelman’s form 4 insider trades.
Insider Ownership Summary of Joseph Edelman
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ARYBU | ARYA Sciences Acquisition Corp II | 2020-10-20 | director |
| ATHA | Athira Pharma Inc | 2021-01-25 | director & 10 percent owner |
| QTNTQ | Quotient Ltd | 2018-12-07 | 10 percent owner |
| ATNXQ | Athenex Inc | 2019-05-03 | 10 percent owner |
| ALBO | Albireo Pharma Inc | 2020-02-03 | 10 percent owner |
| ARYA | ARYA Sciences Acquisition Corp III | 2020-08-06 | director |
| ALDX | Aldeyra Therapeutics Inc | 2020-07-09 | 10 percent owner |
| LPTX | Leap Therapeutics Inc | 2020-03-09 | 10 percent owner |
| SLDB | Solid Biosciences Inc | 2018-01-25 | 10 percent owner |
| VYNE | VYNE Therapeutics Inc | 2020-03-09 | director & 10 percent owner |
| MGTX | MeiraGTx Holdings PLC | 2019-06-19 | 10 percent owner |
| LYRA | Lyra Therapeutics Inc | 2020-04-30 | director & 10 percent owner |
| VBIV | VBI Vaccines Inc | 2018-12-13 | 10 percent owner |
| CRNX | Crinetics Pharmaceuticals Inc | 2020-04-17 | 10 percent owner |
| ADMA | ADMA Biologics Inc | 2019-05-21 | 10 percent owner |
| AGRX | Agile Therapeutics Inc | 2019-03-04 | 10 percent owner |
| KDMN | Kadmon Holdings Inc | 2019-11-18 | 10 percent owner |
| DOVA | Dova Pharmaceuticals Inc | 2019-11-12 | 10 percent owner |
| FOMX | Foamix Pharmaceuticals Ltd | 2019-07-29 | 10 percent owner |
| MOTS | Motus GI Holdings Inc | 2018-02-14 | 10 percent owner |
| FOLD | Amicus Therapeutics Inc | 2018-09-12 | 10 percent owner |
| LJPC | La Jolla Pharmaceutical Co | 2019-01-07 | 10 percent owner |
| CORI | Corium International Inc | 2018-10-11 | 10 percent owner |
| ARYAU | ARYA Sciences Acquisition Corp | 2018-10-05 | director |
| ZGNX | Zogenix Inc | 2018-08-10 | 10 percent owner |
| VRCA | Verrica Pharmaceuticals Inc | 2018-06-14 | 10 percent owner |
| GBT | Global Blood Therapeutics Inc | 2017-12-14 | 10 percent owner |
| ARAV | Aravive Inc | 2017-09-21 | 10 percent owner |
| ACRX | AcelRx Pharmaceuticals Inc | 2017-06-19 | 10 percent owner |
| AEGR | Aegerion Pharmaceuticals Inc | 2013-06-15 | 10 percent owner |
| XTLB | XTL Biopharmaceuticals Ltd | 2008-01-03 | 10 percent owner |
| ANIP | ANI Pharmaceuticals Inc | 2003-08-04 | 10 percent owner |
| ATRS | Antares Pharma Inc | 2004-02-06 | 10 percent owner |
| PTN | Palatin Technologies Inc | 2003-05-29 | 10 percent owner |
| SCYX | SCYNEXIS Inc | 2020-12-21 | 10 percent owner |
| ATXS | Astria Therapeutics Inc | 2021-01-28 | director & 10 percent owner |
| ISO | IsoPlexis Corp | 2021-10-07 | 10 percent owner |
| RXDX | Prometheus Biosciences Inc | 2021-03-11 | 10 percent owner |
| RAIN | Rain Oncology Inc | 2021-04-22 | 10 percent owner |
| LABP | Landos Biopharma Inc | 2021-08-27 | director |
| CERE | Cerevel Therapeutics Holdings Inc | 2020-10-20 | director |
| NAUT | Nautilus Biotechnology Inc | 2021-12-08 | 10 percent owner |
| LIAN | LianBio | 2021-10-29 | 10 percent owner |
| ARYD | ARYA Sciences Acquisition Corp IV | 2021-02-25 | director |
| ARYE | ARYA Sciences Acquisition Corp V | 2021-07-12 | director |
| ACRV | Acrivon Therapeutics Inc | 2022-11-17 | 10 percent owner |
| CEMI | Chembio Diagnostics Inc | 2023-04-04 | 10 percent owner |
| SLNO | Soleno Therapeutics Inc | 2023-05-19 | 10 percent owner |
Joseph Edelman Latest Holdings Summary
Joseph Edelman currently owns a total of 1 stock. Joseph Edelman owns 3,114,805 shares of Athira Pharma Inc (ATHA) as of September 22, 2020, with a value of $6 Million.
Latest Holdings of Joseph Edelman
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ATHA | Athira Pharma Inc | 2020-09-22 | 3,114,805 | 1.98 | 6,167,314 |
Holding Weightings of Joseph Edelman
Joseph Edelman Form 4 Trading Tracker
According to the SEC Form 4 filings, Joseph Edelman has made a total of 1 transactions in Athira Pharma Inc (ATHA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Athira Pharma Inc is the acquisition of 1,058,824 shares on September 22, 2020, which cost Joseph Edelman around $18 Million.
Insider Trading History of Joseph Edelman
- 1
Joseph Edelman Trading Performance
GuruFocus tracks the stock performance after each of Joseph Edelman's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Joseph Edelman is 103.06%. GuruFocus also compares Joseph Edelman's trading performance to market benchmark return within the same time period. The performance of stocks bought by Joseph Edelman within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Joseph Edelman's insider trading performs compared to the benchmark.
Performance of Joseph Edelman
Average Relative Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Relative Return(%) | 20.72 | 103.06 | 14.17 | -40.6 | -55.62 | -50.82 |
| Relative Return to S&P 500(%) | 16.56 | 91.85 | -4.68 | -73.18 | -62.08 | -60.04 |
Joseph Edelman Ownership Network
Ownership Network List of Joseph Edelman
Ownership Network Relation of Joseph Edelman
Joseph Edelman Owned Company Details
What does ARYA Sciences Acquisition Corp II do?
ARYA Sciences Acquisition Corp II is a blank check company.
Who are the key executives at ARYA Sciences Acquisition Corp II?
Joseph Edelman is the director of ARYA Sciences Acquisition Corp II. Other key executives at ARYA Sciences Acquisition Corp II include director & Chief Executive Officer Adam Leo Stone , director & Chief Financial Officer Michael Seth Altman , and 10 percent owner Arya Sciences Holdings Ii .
ARYA Sciences Acquisition Corp II (ARYBU) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of ARYA Sciences Acquisition Corp II (ARYBU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ARYA Sciences Acquisition Corp II (ARYBU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
ARYA Sciences Acquisition Corp II (ARYBU)'s detailed insider trading history can be found in Insider Trading Tracker table.
ARYA Sciences Acquisition Corp II Insider Transactions
- Download to Excel(.xls)
What does Athira Pharma Inc do?
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
Who are the key executives at Athira Pharma Inc?
Joseph Edelman is the director & 10 percent owner of Athira Pharma Inc. Other key executives at Athira Pharma Inc include See Below Andrew Gengos , Chief Technology Officer Rachel Lenington , and General Counsel Mark Worthington .
Athira Pharma Inc (ATHA) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Athira Pharma Inc (ATHA). Other recent insider transactions involving Athira Pharma Inc (ATHA) include a net purchase of 80,012 shares made by Andrew Gengos , a net purchase of 47,386 shares made by Glenna Mileson , and a net purchase of 38,000 shares made by Kelly A Romano .
In summary, during the past 3 months, insiders sold 0 shares of Athira Pharma Inc (ATHA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 19,995 shares of Athira Pharma Inc (ATHA) were sold and 1,584,374 shares were bought by its insiders, resulting in a net purchase of 1,564,379 shares.
Athira Pharma Inc (ATHA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Athira Pharma Inc Insider Transactions
- Download to Excel(.xls)
What does Quotient Ltd do?
Quotient Ltd is a commercial-stage diagnostics company. It is involved in the development, manufacturing, and commercialization of conventional reagent products used for blood grouping within the global transfusion diagnostics market. The company develops and commercializes the Mosaiq automation platform. Its product portfolio includes Reagent Red Blood Cells, Antisera Products, Whole Blood Controls, and Ancillary Products. The firm operates in Edinburgh, Scotland, Eysins, Switzerland, and Newton, Pennsylvania. It derives the majority of its revenue from the United States.
Who are the key executives at Quotient Ltd?
Joseph Edelman is the 10 percent owner of Quotient Ltd. Other key executives at Quotient Ltd include 10 percent owner Highbridge Capital Management Llc , 10 percent owner Quotient Holdings Finance Co Ltd , and 10 percent owner Quotient Holdings Newco, Lp .
Quotient Ltd (QTNTQ) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Quotient Ltd (QTNTQ). Other recent insider transactions involving Quotient Ltd (QTNTQ) include a net purchase of 975,000 shares made by Prondzynski Heino Von , a net sale of 3,223 shares made by Isabelle Buckle , and a net sale of 8,255,607 shares made by Perceptive Life Sciences Master Fund Ltd .
In summary, during the past 3 months, insiders sold 0 shares of Quotient Ltd (QTNTQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 232,513 shares of Quotient Ltd (QTNTQ) were sold and 263,787 shares were bought by its insiders, resulting in a net purchase of 31,274 shares.
Quotient Ltd (QTNTQ)'s detailed insider trading history can be found in Insider Trading Tracker table.
Quotient Ltd Insider Transactions
- Download to Excel(.xls)
What does Athenex Inc do?
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.
Who are the key executives at Athenex Inc?
Joseph Edelman is the 10 percent owner of Athenex Inc. Other key executives at Athenex Inc include Chief Financial Officer Joe Annoni , See Remarks Timothy Devere Cook , and Pres Cell Therapy & VP Corp Dev Daniel Lang .
Athenex Inc (ATNXQ) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Athenex Inc (ATNXQ). Other recent insider transactions involving Athenex Inc (ATNXQ) include a net purchase of 20,000 shares made by Lau Johnson Yiu Nam , and a net purchase of 10,000 shares made by Jinn Wu .
In summary, during the past 3 months, insiders sold 0 shares of Athenex Inc (ATNXQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Athenex Inc (ATNXQ) were sold and 1,500 shares were bought by its insiders, resulting in a net purchase of 1,500 shares.
Athenex Inc (ATNXQ)'s detailed insider trading history can be found in Insider Trading Tracker table.
Athenex Inc Insider Transactions
- Download to Excel(.xls)
What does Albireo Pharma Inc do?
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.
Who are the key executives at Albireo Pharma Inc?
Joseph Edelman is the 10 percent owner of Albireo Pharma Inc. Other key executives at Albireo Pharma Inc include Chief Medical Officer Paul Streck , 10 percent owner Perceptive Advisors Llc , and 10 percent owner Perceptive Life Sciences Master Fund Ltd .
Albireo Pharma Inc (ALBO) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Albireo Pharma Inc (ALBO). Other recent insider transactions involving Albireo Pharma Inc (ALBO) include a net sale of 4,593 shares made by Pamela Stephenson , a net sale of 2,462 shares made by Harford Simon N.r. , and a net sale of 4,731 shares made by Cooper Ronald Harold Wilfred .
In summary, during the past 3 months, insiders sold 0 shares of Albireo Pharma Inc (ALBO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 442,788 shares of Albireo Pharma Inc (ALBO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 442,788 shares.
Albireo Pharma Inc (ALBO)'s detailed insider trading history can be found in Insider Trading Tracker table.
Albireo Pharma Inc Insider Transactions
- Download to Excel(.xls)
What does ARYA Sciences Acquisition Corp III do?
ARYA Sciences Acquisition Corp III is a blank check company.
Who are the key executives at ARYA Sciences Acquisition Corp III?
Joseph Edelman is the director of ARYA Sciences Acquisition Corp III. Other key executives at ARYA Sciences Acquisition Corp III include director & 10 percent owner & Chief Executive Officer Adam Leo Stone , director & 10 percent owner & Chief Financial Officer Michael Seth Altman , and 10 percent owner Arya Sciences Holdings Iii .
ARYA Sciences Acquisition Corp III (ARYA) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of ARYA Sciences Acquisition Corp III (ARYA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ARYA Sciences Acquisition Corp III (ARYA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
ARYA Sciences Acquisition Corp III (ARYA)'s detailed insider trading history can be found in Insider Trading Tracker table.
ARYA Sciences Acquisition Corp III Insider Transactions
- Download to Excel(.xls)
What does Aldeyra Therapeutics Inc do?
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
Who are the key executives at Aldeyra Therapeutics Inc?
Joseph Edelman is the 10 percent owner of Aldeyra Therapeutics Inc. Other key executives at Aldeyra Therapeutics Inc include See Remarks Bruce Greenberg , Chief Development Officer Stephen Machatha , and 10 percent owner Perceptive Advisors Llc .
Aldeyra Therapeutics Inc (ALDX) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Aldeyra Therapeutics Inc (ALDX). Other recent insider transactions involving Aldeyra Therapeutics Inc (ALDX) include a net purchase of 1,305,206 shares made by Perceptive Life Sciences Master Fund Ltd , a net purchase of 17,700 shares made by Todd C Brady , and a net purchase of 4,323 shares made by Martin Joseph Joyce .
In summary, during the past 3 months, insiders sold 0 shares of Aldeyra Therapeutics Inc (ALDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aldeyra Therapeutics Inc (ALDX) were sold and 1,327,229 shares were bought by its insiders, resulting in a net purchase of 1,327,229 shares.
Aldeyra Therapeutics Inc (ALDX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aldeyra Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does Leap Therapeutics Inc do?
Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P204,and P205.
Who are the key executives at Leap Therapeutics Inc?
Joseph Edelman is the 10 percent owner of Leap Therapeutics Inc. Other key executives at Leap Therapeutics Inc include Chief Scientific Officer Jason Baum , VP & Head of Reg Affairs/Qual Christine Granfield , and Chief Medical Officer Cynthia Sirard .
Leap Therapeutics Inc (LPTX) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Leap Therapeutics Inc (LPTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Leap Therapeutics Inc (LPTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Leap Therapeutics Inc (LPTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Leap Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does Solid Biosciences Inc do?
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Who are the key executives at Solid Biosciences Inc?
Joseph Edelman is the 10 percent owner of Solid Biosciences Inc. Other key executives at Solid Biosciences Inc include CFO & Treasurer Kevin Tan , See Remarks David T Howton , and director & President and CEO Alexander Cumbo .
Solid Biosciences Inc (SLDB) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Solid Biosciences Inc (SLDB). Other recent insider transactions involving Solid Biosciences Inc (SLDB) include a net sale of 2,010 shares made by Ilan Ganot , and a net sale of 441 shares made by Carl Ashley Morris .
In summary, during the past 3 months, insiders sold 0 shares of Solid Biosciences Inc (SLDB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 2,451 shares of Solid Biosciences Inc (SLDB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 2,451 shares.
Solid Biosciences Inc (SLDB)'s detailed insider trading history can be found in Insider Trading Tracker table.
Solid Biosciences Inc Insider Transactions
- Download to Excel(.xls)
What does VYNE Therapeutics Inc do?
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its most advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Who are the key executives at VYNE Therapeutics Inc?
Joseph Edelman is the director & 10 percent owner of VYNE Therapeutics Inc. Other key executives at VYNE Therapeutics Inc include Interim CFO Tyler Zeronda , Chief Financial Officer Andrew Saik , and 10 percent owner Perceptive Advisors Llc .
VYNE Therapeutics Inc (VYNE) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in VYNE Therapeutics Inc (VYNE). Other recent insider transactions involving VYNE Therapeutics Inc (VYNE) include a net purchase of 20,000 shares made by Patrick G Lepore , and a net purchase of 10,000 shares made by Mutya Harsch .
In summary, during the past 3 months, insiders sold 0 shares of VYNE Therapeutics Inc (VYNE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of VYNE Therapeutics Inc (VYNE) were sold and 30,000 shares were bought by its insiders, resulting in a net purchase of 30,000 shares.
VYNE Therapeutics Inc (VYNE)'s detailed insider trading history can be found in Insider Trading Tracker table.
VYNE Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does MeiraGTx Holdings PLC do?
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Who are the key executives at MeiraGTx Holdings PLC?
Joseph Edelman is the 10 percent owner of MeiraGTx Holdings PLC. Other key executives at MeiraGTx Holdings PLC include 10 percent owner Johnson & Johnson , 10 percent owner Johnson & Johnson Innovation - Jjdc, Inc. , and Chief Medical Officer Robert K Zeldin .
MeiraGTx Holdings PLC (MGTX) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in MeiraGTx Holdings PLC (MGTX). Other recent insider transactions involving MeiraGTx Holdings PLC (MGTX) include a net purchase of 4,347,826 shares made by Perceptive Life Sciences Master Fund Ltd , a net purchase of 5,000 shares made by Robert K Zeldin , and a net purchase of 1,000 shares made by Robert J Wollin .
In summary, during the past 3 months, insiders sold 0 shares of MeiraGTx Holdings PLC (MGTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of MeiraGTx Holdings PLC (MGTX) were sold and 4,353,826 shares were bought by its insiders, resulting in a net purchase of 4,353,826 shares.
MeiraGTx Holdings PLC (MGTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
MeiraGTx Holdings PLC Insider Transactions
- Download to Excel(.xls)
What does Lyra Therapeutics Inc do?
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Who are the key executives at Lyra Therapeutics Inc?
Joseph Edelman is the director & 10 percent owner of Lyra Therapeutics Inc. Other key executives at Lyra Therapeutics Inc include Chief Technology Officer John E Bishop , Chief Medical Officer Richard Nieman , and director & Executive Chair Harlan Waksal .
Lyra Therapeutics Inc (LYRA) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Lyra Therapeutics Inc (LYRA). Other recent insider transactions involving Lyra Therapeutics Inc (LYRA) include a net purchase of 9,535,002 shares made by Perceptive Life Sciences Master Fund Ltd , a net purchase of 4,293,566 shares made by Edward T Anderson , and a net purchase of 4,175,083 shares made by Nbvm Gp, Llc .
In summary, during the past 3 months, insiders sold 0 shares of Lyra Therapeutics Inc (LYRA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Lyra Therapeutics Inc (LYRA) were sold and 18,248,445 shares were bought by its insiders, resulting in a net purchase of 18,248,445 shares.
Lyra Therapeutics Inc (LYRA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Lyra Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does VBI Vaccines Inc do?
VBI Vaccines Inc is a US-based commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.
Who are the key executives at VBI Vaccines Inc?
Joseph Edelman is the 10 percent owner of VBI Vaccines Inc. Other key executives at VBI Vaccines Inc include Chief Commercial Officer John Robert Dillman , 10 percent owner Perceptive Advisors Llc , and 10 percent owner Perceptive Life Sciences Master Fund Ltd .
VBI Vaccines Inc (VBIV) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in VBI Vaccines Inc (VBIV). Other recent insider transactions involving VBI Vaccines Inc (VBIV) include a net sale of 10,894,749 shares made by Perceptive Life Sciences Master Fund Ltd , and a net purchase of 609,090 shares made by Steven Gillis .
In summary, during the past 3 months, insiders sold 0 shares of VBI Vaccines Inc (VBIV) in total and bought 609,090 shares, with a net purchase of 609,090 shares. During the past 18 months, 363,158 shares of VBI Vaccines Inc (VBIV) were sold and 609,090 shares were bought by its insiders, resulting in a net purchase of 245,932 shares.
VBI Vaccines Inc (VBIV)'s detailed insider trading history can be found in Insider Trading Tracker table.
VBI Vaccines Inc Insider Transactions
- Download to Excel(.xls)
What does Crinetics Pharmaceuticals Inc do?
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Who are the key executives at Crinetics Pharmaceuticals Inc?
Joseph Edelman is the 10 percent owner of Crinetics Pharmaceuticals Inc. Other key executives at Crinetics Pharmaceuticals Inc include Chief Development Officer Dana Pizzuti , Chief Commercial Officer James Hassard , and Chief Scientific Officer Stephen F. Betz .
Crinetics Pharmaceuticals Inc (CRNX) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Crinetics Pharmaceuticals Inc (CRNX). Other recent insider transactions involving Crinetics Pharmaceuticals Inc (CRNX) include a net sale of 67,919 shares made by Stephen F. Betz , a net sale of 260,000 shares made by Richard Scott Struthers , and a net purchase of 157,515 shares made by Perceptive Life Sciences Master Fund Ltd .
In summary, during the past 3 months, insiders sold 50,000 shares of Crinetics Pharmaceuticals Inc (CRNX) in total and bought 0 shares, with a net sale of 50,000 shares. During the past 18 months, 373,905 shares of Crinetics Pharmaceuticals Inc (CRNX) were sold and 162,515 shares were bought by its insiders, resulting in a net sale of 211,390 shares.
Crinetics Pharmaceuticals Inc (CRNX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Crinetics Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does ADMA Biologics Inc do?
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
Who are the key executives at ADMA Biologics Inc?
Joseph Edelman is the 10 percent owner of ADMA Biologics Inc. Other key executives at ADMA Biologics Inc include director & President and CEO Adam S Grossman , EVP & CFO Brian Lenz , and 10 percent owner Perceptive Advisors Llc .
ADMA Biologics Inc (ADMA) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in ADMA Biologics Inc (ADMA). Other recent insider transactions involving ADMA Biologics Inc (ADMA) include a net sale of 730,507 shares made by Adam S Grossman , a net sale of 382,769 shares made by Brian Lenz , and a net sale of 1,433,304 shares made by Bryant Fong .
In summary, during the past 3 months, insiders sold 2,583,538 shares of ADMA Biologics Inc (ADMA) in total and bought 155,000 shares, with a net sale of 2,428,538 shares. During the past 18 months, 2,583,538 shares of ADMA Biologics Inc (ADMA) were sold and 191,958 shares were bought by its insiders, resulting in a net sale of 2,391,580 shares.
ADMA Biologics Inc (ADMA)'s detailed insider trading history can be found in Insider Trading Tracker table.
ADMA Biologics Inc Insider Transactions
- Download to Excel(.xls)
What does Agile Therapeutics Inc do?
Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.
Who are the key executives at Agile Therapeutics Inc?
Joseph Edelman is the 10 percent owner of Agile Therapeutics Inc. Other key executives at Agile Therapeutics Inc include Chief Financial Officer Scott M Coiante , Chief Commercial Officer Amy Welsh , and Principal Accounting Officer Jason Butch .
Agile Therapeutics Inc (AGRX) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Agile Therapeutics Inc (AGRX). Other recent insider transactions involving Agile Therapeutics Inc (AGRX) include a net purchase of 50,000 shares made by Alfred Altomari ,
In summary, during the past 3 months, insiders sold 0 shares of Agile Therapeutics Inc (AGRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Agile Therapeutics Inc (AGRX) were sold and 1,000 shares were bought by its insiders, resulting in a net purchase of 1,000 shares.
Agile Therapeutics Inc (AGRX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Agile Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does Kadmon Holdings Inc do?
Kadmon Holdings Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of small molecules and biologics with a focus on inflammatory and fibrotic diseases. Its pipeline products include Belumosudil (KD025) and KD033.
Who are the key executives at Kadmon Holdings Inc?
Joseph Edelman is the 10 percent owner of Kadmon Holdings Inc. Other key executives at Kadmon Holdings Inc include director & President & CEO Harlan Waksal , Executive Vice President & CMO John L Ryan , and EVP & Chief Financial Officer Steven Meehan .
Kadmon Holdings Inc (KDMN) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Kadmon Holdings Inc (KDMN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kadmon Holdings Inc (KDMN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Kadmon Holdings Inc (KDMN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Kadmon Holdings Inc Insider Transactions
- Download to Excel(.xls)
What does Dova Pharmaceuticals Inc do?
Dova Pharmaceuticals Inc is a United States based clinical-stage pharmaceutical company engaged in developing treatments for patients suffering from orphan diseases. It is focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. The company's drug candidate, avatrombopag, is an orally administered thrombopoietin receptor agonist, or TPO-RA, that it is developing for the treatment of thrombocytopenia. The company's drug candidate, avatrombopag, is designed to mimic the effects of thrombopoietin, in vitro and in vivo. Thrombopoietin is a hormone produced in the liver and kidney that binds to its receptor.
Who are the key executives at Dova Pharmaceuticals Inc?
Joseph Edelman is the 10 percent owner of Dova Pharmaceuticals Inc. Other key executives at Dova Pharmaceuticals Inc include 10 percent owner Perceptive Advisors Llc , 10 percent owner Perceptive Life Sciences Master Fund Ltd , and Chief Medical Officer Allen Lee F Md Phd .
Dova Pharmaceuticals Inc (DOVA) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Dova Pharmaceuticals Inc (DOVA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Dova Pharmaceuticals Inc (DOVA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Dova Pharmaceuticals Inc (DOVA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Dova Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does Foamix Pharmaceuticals Ltd do?
Foamix Pharmaceuticals Ltd is a specialty pharmaceutical company. It is focused on the development and commercialization of foam based formulations and topical drugs for dermatological therapies mainly acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103, FDX104. The firm also has development and license agreements relating to its technology with various pharmaceutical companies. It has The development and commercialization of foam based formulations segment.
Who are the key executives at Foamix Pharmaceuticals Ltd?
Joseph Edelman is the 10 percent owner of Foamix Pharmaceuticals Ltd. Other key executives at Foamix Pharmaceuticals Ltd include Chief Scientific Officer Iain Stuart , director & CEO David Domzalski , and CLO and General Counsel Mutya Harsch .
Foamix Pharmaceuticals Ltd (FOMX) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Foamix Pharmaceuticals Ltd (FOMX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Foamix Pharmaceuticals Ltd (FOMX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Foamix Pharmaceuticals Ltd (FOMX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Foamix Pharmaceuticals Ltd Insider Transactions
- Download to Excel(.xls)
What does Motus GI Holdings Inc do?
Motus GI Holdings Inc is a medical technology company dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. The company has developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the "FDA") to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal ("GI") endoscopy procedures. The Pure-Vu System is also CE marked in the European Economic Area (EEA) for use in colonoscopy.
Who are the key executives at Motus GI Holdings Inc?
Joseph Edelman is the 10 percent owner of Motus GI Holdings Inc. Other key executives at Motus GI Holdings Inc include Chief Financial Officer Ravit Ram , Chief Accounting Officer Elad Amor , and other: * See Remarks Oracle Partners Lp .
Motus GI Holdings Inc (MOTS) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Motus GI Holdings Inc (MOTS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Motus GI Holdings Inc (MOTS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Motus GI Holdings Inc (MOTS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Motus GI Holdings Inc Insider Transactions
- Download to Excel(.xls)
What does Amicus Therapeutics Inc do?
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
Who are the key executives at Amicus Therapeutics Inc?
Joseph Edelman is the 10 percent owner of Amicus Therapeutics Inc. Other key executives at Amicus Therapeutics Inc include Chief Financial Officer Harford Simon N.r. , director & President & CEO Bradley L Campbell , and director & Executive Chairman John F Crowley .
Amicus Therapeutics Inc (FOLD) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Amicus Therapeutics Inc (FOLD). Other recent insider transactions involving Amicus Therapeutics Inc (FOLD) include a net sale of 508,059 shares made by John F Crowley , a net sale of 202,438 shares made by Bradley L Campbell , and a net sale of 65,102 shares made by Ellen Rosenberg .
In summary, during the past 3 months, insiders sold 131,266 shares of Amicus Therapeutics Inc (FOLD) in total and bought 0 shares, with a net sale of 131,266 shares. During the past 18 months, 937,134 shares of Amicus Therapeutics Inc (FOLD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 937,134 shares.
Amicus Therapeutics Inc (FOLD)'s detailed insider trading history can be found in Insider Trading Tracker table.
Amicus Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does La Jolla Pharmaceutical Co do?
La Jolla Pharmaceutical Co is a biopharmaceutical company. The company's main activity is the discovery, development, and commercialization of innovative therapies that improve patients' life-threatening conditions. The company's portfolio consists of an angiotensin II formulation, which regulates blood pressure; a formulation of hepcidin, an endogenous peptide hormone that regulates iron metabolism; and an antibiotic approved by the U.S. Food and Drug Administration.
Who are the key executives at La Jolla Pharmaceutical Co?
Joseph Edelman is the 10 percent owner of La Jolla Pharmaceutical Co. Other key executives at La Jolla Pharmaceutical Co include director & 10 percent owner Kevin C Tang , Chief Financial Officer Michael S Hearne , and director & Chief Executive Officer Larry G. Edwards .
La Jolla Pharmaceutical Co (LJPC) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of La Jolla Pharmaceutical Co (LJPC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of La Jolla Pharmaceutical Co (LJPC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
La Jolla Pharmaceutical Co (LJPC)'s detailed insider trading history can be found in Insider Trading Tracker table.
La Jolla Pharmaceutical Co Insider Transactions
- Download to Excel(.xls)
What does Corium International Inc do?
Corium International Inc is a commercial-stage biopharmaceutical company which is focused on the development, manufacture, and commercialization of specialty pharmaceutical products. The company has multiple proprietary programs in preclinical and clinical development focusing primarily on the treatment of neurological disorders. It has few proprietary transdermal platforms such as Corplex for small molecules and MicroCor which is a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides, and proteins. The company's products include Clonidine TDS, Fentanyl TDS, and Crest Whitestrips.
Who are the key executives at Corium International Inc?
Joseph Edelman is the 10 percent owner of Corium International Inc. Other key executives at Corium International Inc include 10 percent owner Broadfin Healthcare Master Fund Ltd , 10 percent owner Broadfin Capital, Llc , and 10 percent owner Kevin Kotler .
Corium International Inc (CORI) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Corium International Inc (CORI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Corium International Inc (CORI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Corium International Inc (CORI)'s detailed insider trading history can be found in Insider Trading Tracker table.
Corium International Inc Insider Transactions
- Download to Excel(.xls)
What does ARYA Sciences Acquisition Corp do?
ARYA Sciences Acquisition Corp is a blank check company.
Who are the key executives at ARYA Sciences Acquisition Corp?
Joseph Edelman is the director of ARYA Sciences Acquisition Corp. Other key executives at ARYA Sciences Acquisition Corp include director & Chief Executive Officer Adam Leo Stone , and director & Chief Financial Officer Michael Seth Altman .
ARYA Sciences Acquisition Corp (ARYAU) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of ARYA Sciences Acquisition Corp (ARYAU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ARYA Sciences Acquisition Corp (ARYAU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
ARYA Sciences Acquisition Corp (ARYAU)'s detailed insider trading history can be found in Insider Trading Tracker table.
ARYA Sciences Acquisition Corp Insider Transactions
- Download to Excel(.xls)
What does Zogenix Inc do?
Zogenix Inc is engaged in developing and commercializing therapeutic solutions for people living with serious and life-threatening rare CNS disorders and medical conditions. Its product candidate includes ZX008, low-dose fenfluramine for the treatment of Dravet syndrome, LGS, and potentially other rare and catastrophic epilepsy disorders.
Who are the key executives at Zogenix Inc?
Joseph Edelman is the 10 percent owner of Zogenix Inc. Other key executives at Zogenix Inc include EVP & CHIEF COMMERCIAL OFFICER Ashish M Sagrolikar , EVP/Chief Development Officer Gail M Farfel , and director & President and CEO Stephen J Farr .
Zogenix Inc (ZGNX) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Zogenix Inc (ZGNX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Zogenix Inc (ZGNX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Zogenix Inc (ZGNX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Zogenix Inc Insider Transactions
- Download to Excel(.xls)
What does Verrica Pharmaceuticals Inc do?
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts.
Who are the key executives at Verrica Pharmaceuticals Inc?
Joseph Edelman is the 10 percent owner of Verrica Pharmaceuticals Inc. Other key executives at Verrica Pharmaceuticals Inc include Chief Financial Officer Terry Kohler , General Counsel Christopher G. Hayes , and Chief Financial Officer A Brian Davis .
Verrica Pharmaceuticals Inc (VRCA) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Verrica Pharmaceuticals Inc (VRCA). Other recent insider transactions involving Verrica Pharmaceuticals Inc (VRCA) include a net sale of 26,289 shares made by Christopher G. Hayes , a net purchase of 1,428,571 shares made by Perceptive Life Sciences Master Fund Ltd , and a net purchase of 200,000 shares made by Paul B Manning .
In summary, during the past 3 months, insiders sold 151,427 shares of Verrica Pharmaceuticals Inc (VRCA) in total and bought 200,000 shares, with a net purchase of 48,573 shares. During the past 18 months, 151,427 shares of Verrica Pharmaceuticals Inc (VRCA) were sold and 1,636,071 shares were bought by its insiders, resulting in a net purchase of 1,484,644 shares.
Verrica Pharmaceuticals Inc (VRCA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Verrica Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does Global Blood Therapeutics Inc do?
Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.
Who are the key executives at Global Blood Therapeutics Inc?
Joseph Edelman is the 10 percent owner of Global Blood Therapeutics Inc. Other key executives at Global Blood Therapeutics Inc include See Remarks Nazila Habibizad , Chief Human Resources Officer Carrie Krehlik , and See Remarks Kim Smith-whitley .
Global Blood Therapeutics Inc (GBT) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Global Blood Therapeutics Inc (GBT). Other recent insider transactions involving Global Blood Therapeutics Inc (GBT) include a net sale of 31,441 shares made by Jeffrey S Farrow , a net sale of 4,678 shares made by Nazila Habibizad , and a net sale of 1,908 shares made by Dawn Svoronos .
In summary, during the past 3 months, insiders sold 0 shares of Global Blood Therapeutics Inc (GBT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 39,287 shares of Global Blood Therapeutics Inc (GBT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 39,287 shares.
Global Blood Therapeutics Inc (GBT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Global Blood Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does Aravive Inc do?
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.
Who are the key executives at Aravive Inc?
Joseph Edelman is the 10 percent owner of Aravive Inc. Other key executives at Aravive Inc include Chief Commercial Officer Maria Carolina Petrini , Chief Medical Officer Robert B. Geller , and Chief Financial Officer Rudy Howard .
Aravive Inc (ARAV) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Aravive Inc (ARAV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aravive Inc (ARAV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Aravive Inc (ARAV)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aravive Inc Insider Transactions
- Download to Excel(.xls)
What does AcelRx Pharmaceuticals Inc do?
AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain.
Who are the key executives at AcelRx Pharmaceuticals Inc?
Joseph Edelman is the 10 percent owner of AcelRx Pharmaceuticals Inc. Other key executives at AcelRx Pharmaceuticals Inc include director & Chief Medical Officer Pamela P Palmer , director & Chief Executive Officer Vincent J. Angotti , and Chief Development Officer Lawrence G Hamel .
AcelRx Pharmaceuticals Inc (ACRX) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in AcelRx Pharmaceuticals Inc (ACRX). Other recent insider transactions involving AcelRx Pharmaceuticals Inc (ACRX) include a net purchase of 56,400 shares made by Vincent J. Angotti , and a net sale of 16,956 shares made by Pamela P Palmer .
In summary, during the past 3 months, insiders sold 16,956 shares of AcelRx Pharmaceuticals Inc (ACRX) in total and bought 10,000 shares, with a net sale of 6,956 shares. During the past 18 months, 16,956 shares of AcelRx Pharmaceuticals Inc (ACRX) were sold and 12,320 shares were bought by its insiders, resulting in a net sale of 4,636 shares.
AcelRx Pharmaceuticals Inc (ACRX)'s detailed insider trading history can be found in Insider Trading Tracker table.
AcelRx Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does Aegerion Pharmaceuticals Inc do?
Aegerion Pharmaceuticals, Inc. was incorporated in February 2005. The Company is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company currently operates in one business segment focusing on the development and commercialization of its product, lomitapide. The product, lomitapide, received marketing approval, under the brand name JUXTAPID (lomitapide) capsules ("JUXTAPID"). It is an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein ("LDL") apheresis where available, to reduce low-density lipoprotein cholesterol ("LDL-C"), total cholesterol ("TC"), apolipoprotein B ("apo B") and non-high-density lipoprotein cholesterol ("non-HDL-C") in adult patients with homozygous familial hypercholesterolemia ("HoFH"). Lomitapide is also approved for the treatment of HoFH in Norway, Iceland, Mexico and Canada. The Company also sells lomitapide, on a named patient basis, in Brazil and in a limited number of other countries outside the U.S. and the EU where such sales are authorized based on the U.S. or the EU approval. The Company also launched JUXTAPID in the U.S. The Company relies on a contract manufacturer to produce drug substance for lomitapide and another contract manufacturer for drug product for its clinical trials and for commercial supplies. It distributes JUXTAPID through a specialty pharmacy that distributes JUXTAPID directly to patients and, under limited circumstances, to other purchasers. The lomitapide patent portfolio consists of five issued U.S. patents and issued patents in Europe, Canada, Israel, Australia, New Zealand and Japan and pending applications in the U.S., Australia, Japan, Canada, India and South Korea, all of which have been licensed in a specific field. The Company competes with Regeneron Pharmaceuticals, Inc., in collaboration with Sanofi, Roche Holding AG, Pfizer Inc., Amgen Inc., and Alnylam Pharmaceuticals, Inc. The Company's operations are subject to federal, state and local level, the EU and other countries extensively regulations.
Who are the key executives at Aegerion Pharmaceuticals Inc?
Joseph Edelman is the 10 percent owner of Aegerion Pharmaceuticals Inc. Other key executives at Aegerion Pharmaceuticals Inc include director & Chief Executive Officer Mary T Szela , other: See Remarks Gregory D Perry , and 10 percent owner Broadfin Healthcare Master Fund Ltd .
Aegerion Pharmaceuticals Inc (AEGR) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Aegerion Pharmaceuticals Inc (AEGR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aegerion Pharmaceuticals Inc (AEGR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Aegerion Pharmaceuticals Inc (AEGR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aegerion Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does XTL Biopharmaceuticals Ltd do?
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Who are the key executives at XTL Biopharmaceuticals Ltd?
Joseph Edelman is the 10 percent owner of XTL Biopharmaceuticals Ltd. Other key executives at XTL Biopharmaceuticals Ltd include 10 percent owner Perceptive Advisors Llc , 10 percent owner Perceptive Life Sciences Master Fund Ltd , and 10 percent owner Michael Cho .
XTL Biopharmaceuticals Ltd (XTLB) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of XTL Biopharmaceuticals Ltd (XTLB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of XTL Biopharmaceuticals Ltd (XTLB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
XTL Biopharmaceuticals Ltd (XTLB)'s detailed insider trading history can be found in Insider Trading Tracker table.
XTL Biopharmaceuticals Ltd Insider Transactions
- Download to Excel(.xls)
What does ANI Pharmaceuticals Inc do?
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Who are the key executives at ANI Pharmaceuticals Inc?
Joseph Edelman is the 10 percent owner of ANI Pharmaceuticals Inc. Other key executives at ANI Pharmaceuticals Inc include director & PRESIDENT & CEO Nikhil Lalwani , SVP & CHIEF HR OFFICER Krista Davis , and SVP - CORP. DEV. & STRATEGY Chad Gassert .
ANI Pharmaceuticals Inc (ANIP) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in ANI Pharmaceuticals Inc (ANIP). Other recent insider transactions involving ANI Pharmaceuticals Inc (ANIP) include a net sale of 290,000 shares made by Muthusamy Shanmugam , a net sale of 80,000 shares made by Chad Gassert , and a net sale of 400,000 shares made by Meridian Venture Partners Ii Lp .
In summary, during the past 3 months, insiders sold 568,414 shares of ANI Pharmaceuticals Inc (ANIP) in total and bought 0 shares, with a net sale of 568,414 shares. During the past 18 months, 896,480 shares of ANI Pharmaceuticals Inc (ANIP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 896,480 shares.
ANI Pharmaceuticals Inc (ANIP)'s detailed insider trading history can be found in Insider Trading Tracker table.
ANI Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does Antares Pharma Inc do?
Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.
Who are the key executives at Antares Pharma Inc?
Joseph Edelman is the 10 percent owner of Antares Pharma Inc. Other key executives at Antares Pharma Inc include See Remarks Peter C Richardson , Executive Vice President & CFO Fred M Powell , and See Remarks Peter J Graham .
Antares Pharma Inc (ATRS) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Antares Pharma Inc (ATRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Antares Pharma Inc (ATRS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Antares Pharma Inc (ATRS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Antares Pharma Inc Insider Transactions
- Download to Excel(.xls)
What does Palatin Technologies Inc do?
Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.
Who are the key executives at Palatin Technologies Inc?
Joseph Edelman is the 10 percent owner of Palatin Technologies Inc. Other key executives at Palatin Technologies Inc include other: See Explanation of Responses Biotechnology Value Fund L P , 10 percent owner Bvf Partners L P/il , and 10 percent owner Bvf Inc/il .
Palatin Technologies Inc (PTN) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Palatin Technologies Inc (PTN). Other recent insider transactions involving Palatin Technologies Inc (PTN) include a net purchase of 10,000 shares made by Stephen T Wills , a net purchase of 10,000 shares made by Carl Spana , and a net sale of 200 shares made by Alan W Dunton .
In summary, during the past 3 months, insiders sold 0 shares of Palatin Technologies Inc (PTN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 200 shares of Palatin Technologies Inc (PTN) were sold and 20,000 shares were bought by its insiders, resulting in a net purchase of 19,800 shares.
Palatin Technologies Inc (PTN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Palatin Technologies Inc Insider Transactions
- Download to Excel(.xls)
What does SCYNEXIS Inc do?
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.
Who are the key executives at SCYNEXIS Inc?
Joseph Edelman is the 10 percent owner of SCYNEXIS Inc. Other key executives at SCYNEXIS Inc include Chief Financial Officer Ivor Macleod , Interim CFO Lawrence R Hoffman , and Chief Commercial Officer Christine Coyne .
SCYNEXIS Inc (SCYX) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in SCYNEXIS Inc (SCYX). Other recent insider transactions involving SCYNEXIS Inc (SCYX) include a net purchase of 75,000 shares made by Marco Taglietti , and a net purchase of 3,500 shares made by Scott Sukenick .
In summary, during the past 3 months, insiders sold 0 shares of SCYNEXIS Inc (SCYX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of SCYNEXIS Inc (SCYX) were sold and 78,500 shares were bought by its insiders, resulting in a net purchase of 78,500 shares.
SCYNEXIS Inc (SCYX)'s detailed insider trading history can be found in Insider Trading Tracker table.
SCYNEXIS Inc Insider Transactions
- Download to Excel(.xls)
What does Astria Therapeutics Inc do?
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.
Who are the key executives at Astria Therapeutics Inc?
Joseph Edelman is the director & 10 percent owner of Astria Therapeutics Inc. Other key executives at Astria Therapeutics Inc include Chief Business Officer Andrea Matthews , Chief Medical Officer Christopher Morabito , and Chief Commercial Officer Andrew Komjathy .
Astria Therapeutics Inc (ATXS) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Astria Therapeutics Inc (ATXS). Other recent insider transactions involving Astria Therapeutics Inc (ATXS) include a net purchase of 908,265 shares made by Perceptive Life Sciences Master Fund Ltd ,
In summary, during the past 3 months, insiders sold 0 shares of Astria Therapeutics Inc (ATXS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Astria Therapeutics Inc (ATXS) were sold and 908,265 shares were bought by its insiders, resulting in a net purchase of 908,265 shares.
Astria Therapeutics Inc (ATXS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Astria Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does IsoPlexis Corp do?
IsoPlexis Corp is a developer of a single-cell detection system designed to accelerate insights in the field of cancer. It designed a platform to reveal functional protein biology and cellular signaling networks at single-cell resolution to accelerate the development of advanced medicines.
Who are the key executives at IsoPlexis Corp?
Joseph Edelman is the 10 percent owner of IsoPlexis Corp. Other key executives at IsoPlexis Corp include director & 10 percent owner Gregory P. Ho , director & Chief Executive Officer Sean Mackay , and Chief Commercial Officer Peter Siesel .
IsoPlexis Corp (ISO) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in IsoPlexis Corp (ISO). Other recent insider transactions involving IsoPlexis Corp (ISO) include a net purchase of 50,253 shares made by Nachum Shamir , a net purchase of 20,000 shares made by Rew Richard W. Ii , and a net purchase of 15,000 shares made by Sean Mackay .
In summary, during the past 3 months, insiders sold 0 shares of IsoPlexis Corp (ISO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of IsoPlexis Corp (ISO) were sold and 95,253 shares were bought by its insiders, resulting in a net purchase of 95,253 shares.
IsoPlexis Corp (ISO)'s detailed insider trading history can be found in Insider Trading Tracker table.
IsoPlexis Corp Insider Transactions
- Download to Excel(.xls)
What does Prometheus Biosciences Inc do?
Prometheus Biosciences Inc is a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD.
Who are the key executives at Prometheus Biosciences Inc?
Joseph Edelman is the 10 percent owner of Prometheus Biosciences Inc. Other key executives at Prometheus Biosciences Inc include 10 percent owner Cedars Sinai Intellectual Property Co , 10 percent owner Roderick Wong , and 10 percent owner Point72 Biotech Private Investments, Llc .
Prometheus Biosciences Inc (RXDX) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Prometheus Biosciences Inc (RXDX). Other recent insider transactions involving Prometheus Biosciences Inc (RXDX) include a net sale of 125,000 shares made by Mark C. Mckenna , a net sale of 30,000 shares made by Keith W Marshall , and a net sale of 865,000 shares made by Cedars Sinai Intellectual Property Co .
In summary, during the past 3 months, insiders sold 0 shares of Prometheus Biosciences Inc (RXDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,020,000 shares of Prometheus Biosciences Inc (RXDX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,020,000 shares.
Prometheus Biosciences Inc (RXDX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Prometheus Biosciences Inc Insider Transactions
- Download to Excel(.xls)
What does Rain Oncology Inc do?
Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Who are the key executives at Rain Oncology Inc?
Joseph Edelman is the 10 percent owner of Rain Oncology Inc. Other key executives at Rain Oncology Inc include Principal Fin. & Acc. Officer Josephine Bruce , 10 percent owner Kevin C Tang , and 10 percent owner Tang Capital Management Llc .
Rain Oncology Inc (RAIN) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Rain Oncology Inc (RAIN). Other recent insider transactions involving Rain Oncology Inc (RAIN) include a net purchase of 164,881 shares made by Franklin M Berger , a net purchase of 1,710,358 shares made by Biotechnology Value Fund L P , and a net purchase of 1,088,273 shares made by Kevin C Tang .
In summary, during the past 3 months, insiders sold 0 shares of Rain Oncology Inc (RAIN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 995,000 shares of Rain Oncology Inc (RAIN) were sold and 3,960,724 shares were bought by its insiders, resulting in a net purchase of 2,965,724 shares.
Rain Oncology Inc (RAIN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Rain Oncology Inc Insider Transactions
- Download to Excel(.xls)
What does Landos Biopharma Inc do?
Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. It operates in one reportable segment of operations and manages.
Who are the key executives at Landos Biopharma Inc?
Joseph Edelman is the director of Landos Biopharma Inc. Other key executives at Landos Biopharma Inc include 10 percent owner Perceptive Xontogeny Venture Fund Ii, Lp , 10 percent owner Roderick Wong , and 10 percent owner Rtw Investments, Lp .
Landos Biopharma Inc (LABP) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Landos Biopharma Inc (LABP). Other recent insider transactions involving Landos Biopharma Inc (LABP) include a net sale of 300,000 shares made by Rtw Investments, Lp ,
In summary, during the past 3 months, insiders sold 0 shares of Landos Biopharma Inc (LABP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 300,000 shares of Landos Biopharma Inc (LABP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 300,000 shares.
Landos Biopharma Inc (LABP)'s detailed insider trading history can be found in Insider Trading Tracker table.
Landos Biopharma Inc Insider Transactions
- Download to Excel(.xls)
What does Cerevel Therapeutics Holdings Inc do?
Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.
Who are the key executives at Cerevel Therapeutics Holdings Inc?
Joseph Edelman is the director of Cerevel Therapeutics Holdings Inc. Other key executives at Cerevel Therapeutics Holdings Inc include See Remarks Paul D. Burgess , director & President & CEO Renaud Ronald C Jr , and Chief Financial Officer Susan Altschuller .
Cerevel Therapeutics Holdings Inc (CERE) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Cerevel Therapeutics Holdings Inc (CERE). Other recent insider transactions involving Cerevel Therapeutics Holdings Inc (CERE) include a net sale of 450,000 shares made by N Anthony Coles , a net sale of 241,105 shares made by John Renger , and a net sale of 96,056 shares made by Abraham Ceesay .
In summary, during the past 3 months, insiders sold 100,000 shares of Cerevel Therapeutics Holdings Inc (CERE) in total and bought 105,737 shares, with a net purchase of 5,737 shares. During the past 18 months, 1,046,761 shares of Cerevel Therapeutics Holdings Inc (CERE) were sold and 1,530,737 shares were bought by its insiders, resulting in a net purchase of 483,976 shares.
Cerevel Therapeutics Holdings Inc (CERE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Cerevel Therapeutics Holdings Inc Insider Transactions
- Download to Excel(.xls)
What does Nautilus Biotechnology Inc do?
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
Who are the key executives at Nautilus Biotechnology Inc?
Joseph Edelman is the 10 percent owner of Nautilus Biotechnology Inc. Other key executives at Nautilus Biotechnology Inc include Senior VP & Operations Mary E. Godwin , Chief People Officer Gwen E Weld , and 10 percent owner Perceptive Life Sciences Master Fund Ltd .
Nautilus Biotechnology Inc (NAUT) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Nautilus Biotechnology Inc (NAUT). Other recent insider transactions involving Nautilus Biotechnology Inc (NAUT) include a net purchase of 100,000 shares made by Sujal M Patel , a net purchase of 90,000 shares made by Subramanian Sankar , and a net purchase of 23,000 shares made by Anna Mowry .
In summary, during the past 3 months, insiders sold 0 shares of Nautilus Biotechnology Inc (NAUT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Nautilus Biotechnology Inc (NAUT) were sold and 253,000 shares were bought by its insiders, resulting in a net purchase of 253,000 shares.
Nautilus Biotechnology Inc (NAUT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Nautilus Biotechnology Inc Insider Transactions
- Download to Excel(.xls)
What does LianBio do?
LianBio is a science-driven biopharmaceutical company dedicated to developing and commercializing medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. It is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease, and respiratory indications.
Who are the key executives at LianBio?
Joseph Edelman is the 10 percent owner of LianBio. Other key executives at LianBio include director & 10 percent owner Perceptive Advisors Llc , 10 percent owner Perceptive Life Sciences Master Fund Ltd , and Chief Financial Officer Yi Larson .
LianBio (LIAN) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in LianBio (LIAN). Other recent insider transactions involving LianBio (LIAN) include a net purchase of 1,238,491 shares made by Perceptive Life Sciences Master Fund Ltd ,
In summary, during the past 3 months, insiders sold 0 shares of LianBio (LIAN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of LianBio (LIAN) were sold and 1,238,491 shares were bought by its insiders, resulting in a net purchase of 1,238,491 shares.
LianBio (LIAN)'s detailed insider trading history can be found in Insider Trading Tracker table.
LianBio Insider Transactions
- Download to Excel(.xls)
What does ARYA Sciences Acquisition Corp IV do?
ARYA Sciences Acquisition Corp IV is a blank check company.
Who are the key executives at ARYA Sciences Acquisition Corp IV?
Joseph Edelman is the director of ARYA Sciences Acquisition Corp IV. Other key executives at ARYA Sciences Acquisition Corp IV include Chief Business Officer Konstantin Poukalov , director & 10 percent owner & Chief Executive Officer Adam Leo Stone , and director & 10 percent owner & Chief Financial Officer Michael Seth Altman .
ARYA Sciences Acquisition Corp IV (ARYD) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of ARYA Sciences Acquisition Corp IV (ARYD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ARYA Sciences Acquisition Corp IV (ARYD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
ARYA Sciences Acquisition Corp IV (ARYD)'s detailed insider trading history can be found in Insider Trading Tracker table.
ARYA Sciences Acquisition Corp IV Insider Transactions
- Download to Excel(.xls)
What does ARYA Sciences Acquisition Corp V do?
ARYA Sciences Acquisition Corp V is a blank check company.
Who are the key executives at ARYA Sciences Acquisition Corp V?
Joseph Edelman is the director of ARYA Sciences Acquisition Corp V. Other key executives at ARYA Sciences Acquisition Corp V include Chief Business Officer Konstantin Poukalov , director & 10 percent owner & Chief Executive Officer Adam Leo Stone , and director & 10 percent owner & Chief Financial Officer Michael Seth Altman .
ARYA Sciences Acquisition Corp V (ARYE) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of ARYA Sciences Acquisition Corp V (ARYE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ARYA Sciences Acquisition Corp V (ARYE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
ARYA Sciences Acquisition Corp V (ARYE)'s detailed insider trading history can be found in Insider Trading Tracker table.
ARYA Sciences Acquisition Corp V Insider Transactions
- Download to Excel(.xls)
What does Acrivon Therapeutics Inc do?
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Who are the key executives at Acrivon Therapeutics Inc?
Joseph Edelman is the 10 percent owner of Acrivon Therapeutics Inc. Other key executives at Acrivon Therapeutics Inc include director & President and CEO Peter Blume-jensen , Chief Financial Officer Rasmus Holm-jorgensen , and Chief Operating Officer Eric Devroe .
Acrivon Therapeutics Inc (ACRV) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Acrivon Therapeutics Inc (ACRV). Other recent insider transactions involving Acrivon Therapeutics Inc (ACRV) include a net purchase of 392,035 shares made by Chione Ltd , and a net purchase of 3,389,500 shares made by Ra Capital Healthcare Fund Lp .
In summary, during the past 3 months, insiders sold 16 shares of Acrivon Therapeutics Inc (ACRV) in total and bought 0 shares, with a net sale of 16 shares. During the past 18 months, 7,965 shares of Acrivon Therapeutics Inc (ACRV) were sold and 3,789,500 shares were bought by its insiders, resulting in a net purchase of 3,781,535 shares.
Acrivon Therapeutics Inc (ACRV)'s detailed insider trading history can be found in Insider Trading Tracker table.
Acrivon Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does Chembio Diagnostics Inc do?
Chembio Diagnostics Inc is a company that develops, manufactures, and commercializes point-of-care diagnostic tests that detect infectious diseases. The products of the company include rapid tests for the detection of HIV 1/2 antibodies and a multiplex rapid test for the detection of HIV and syphilis antibodies. The company offered rapid medical tests that are offered in Africa, Asia, Europe, and the Middle East, Latin America and the United States, of which key revenue is derived from Latin America.
Who are the key executives at Chembio Diagnostics Inc?
Joseph Edelman is the 10 percent owner of Chembio Diagnostics Inc. Other key executives at Chembio Diagnostics Inc include 10 percent owner Perceptive Credit Advisors, Llc , 10 percent owner Perceptive Advisors Llc , and See remarks Paul Angelico .
Chembio Diagnostics Inc (CEMI) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Chembio Diagnostics Inc (CEMI). Other recent insider transactions involving Chembio Diagnostics Inc (CEMI) include a net purchase of 1,490,120 shares made by Perceptive Credit Advisors, Llc ,
In summary, during the past 3 months, insiders sold 0 shares of Chembio Diagnostics Inc (CEMI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Chembio Diagnostics Inc (CEMI) were sold and 1,490,120 shares were bought by its insiders, resulting in a net purchase of 1,490,120 shares.
Chembio Diagnostics Inc (CEMI)'s detailed insider trading history can be found in Insider Trading Tracker table.
Chembio Diagnostics Inc Insider Transactions
- Download to Excel(.xls)
What does Soleno Therapeutics Inc do?
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome.
Who are the key executives at Soleno Therapeutics Inc?
Joseph Edelman is the 10 percent owner of Soleno Therapeutics Inc. Other key executives at Soleno Therapeutics Inc include 10 percent owner Perceptive Advisors Llc , 10 percent owner Perceptive Life Sciences Master Fund Ltd , and 10 percent owner Vivo Opportunity Fund Holdings, L.p. .
Soleno Therapeutics Inc (SLNO) Insider Trades Summary
Over the past 18 months, Joseph Edelman made no insider transaction in Soleno Therapeutics Inc (SLNO). Other recent insider transactions involving Soleno Therapeutics Inc (SLNO) include a net purchase of 343,298 shares made by Perceptive Life Sciences Master Fund Ltd , and a net sale of 610,594 shares made by Jack W Schuler .
In summary, during the past 3 months, insiders sold 0 shares of Soleno Therapeutics Inc (SLNO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 610,594 shares of Soleno Therapeutics Inc (SLNO) were sold and 343,298 shares were bought by its insiders, resulting in a net sale of 267,296 shares.
Soleno Therapeutics Inc (SLNO)'s detailed insider trading history can be found in Insider Trading Tracker table.
Soleno Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
Joseph Edelman Mailing Address
Above is the net worth, insider trading, and ownership report for Joseph Edelman. You might contact Joseph Edelman via mailing address: C/o Perceptive Advisors Llc, 51 Astor Place, 10th Floor, New York Ny 10003.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
